Table 1.
Total (n = 257) | Non-deterioration (n = 208) | Deterioration (n = 49) | p Value | |
---|---|---|---|---|
Age, years | 46 ± 17 | 43 ± 16 | 60 ± 13) | <.001** |
Sex | ||||
Male | 140 (54) | 111 (43) | 29 (11) | .462 |
Length of stay | 18 ± 10 | 17 ± 8 | 25 ± 16 | <.001** |
Current smoker | 27 (10.5) | 21 (10.1) | 6 (12.2) | .659 |
Signs and symptoms at admission | ||||
Cough | 138 (63.7) | 106 (51) | 32 (65.3) | .07 |
Sputum | 81 (31.5) | 61 (29.3) | 20 (40.8) | .119 |
Myalgia | 93 (36.2) | 61 (29.3) | 32 (65.3) | <.001** |
Headache | 34 (13.2) | 25 (12) | 9 (18.4) | .238 |
Rhinorrhea | 17 (6.6) | 13 (6.3) | 4 (8.2) | .748 |
Dyspnea | 43 (16.7) | 25 (12) | 18 (36.7) | <.001** |
Comorbidity | ||||
Hypertension | 53 (20.6) | 33 (15.9) | 20 (40.8) | <.001** |
Diabetes | 15 (5.8) | 9 (4.3) | 6 (12.2) | .045* |
Coronary heart disease | 16 (6.2) | 10 (4.8) | 6 (12.2) | .091 |
Cerebrovascular disease | 8 (3.1) | 5 (2.4) | 3 (6.1) | .18 |
Chronic obstructive lung disease | 2 (0.8) | 1 (0.5) | 1 (2) | .346 |
Carcinoma | 6 (2.3) | 3 (1.4) | 3 (6.1) | .085 |
Chronic kidney disease | 4 (1.6) | 2 (1) | 2 (4.1) | .165 |
Hepatitis B | 12 (4.7) | 9 (4.3) | 3 (6.1) | .705 |
Tuberculosis | 3 (1.2) | 3 (1.4) | 0 | 1 |
Medical history | ||||
ACEI/ARB | 26 (10.1) | 16 (7.7) | 10 (20.4) | .008* |
CCB | 32 (12.5) | 21 (10.1) | 11 (22.4) | .018* |
Diuretic | 3 (1.2) | 2 (1) | 1 (2) | .471 |
β-blocker | 15 (5.8) | 11 (5.3) | 4 (8.2) | .496 |
Metformin | 9 (3.5) | 5 (2.4) | 4 (8.2) | .07 |
Vital signs at admission | ||||
Respiratory rate | 19 ± 2 | 19 ± 2 | 20 ± 2 | <.001** |
Fever (temperature ≥ 37.3 °C) | 156 (60.7) | 116 (55.8) | 40 (81.6) | <.001** |
Pulse, beats per min | 86 ± 13 | 86 ± 13 | 87 ± 14 | .65 |
Systolic blood pressure, mmHg | 126 ± 18 | 124 ± 17 | 135 ± 19 | .001** |
Diastolic blood pressure, mmHg | 82 ± 11 | 82 ± 10 | 83 ± 14 | .29 |
Summary statistics are means ± SD or n (%). p Values were calculated by Mann–Whitney U test, χ² test, or Fisher’s exact test, as appropriate.
Abbreviations. ACEI, Angiotensin-converting enzyme inhibitor; ARB, Angiotensin receptor blocker; CCB, Calcium channel blocker.
*p ≤ .05; **p ≤ .001.